Eupraxia Pharmaceuticals Inc. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2024: USD 10.37 M

Eupraxia Pharmaceuticals Inc. Selling, General, and Administrative Expenses (SG&A) is USD 10.37 M for the year ending December 31, 2024, a 42.42% change year over year. Selling, general, and administrative (SG&A) expenses are the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company.
  • Eupraxia Pharmaceuticals Inc. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2023 was USD 7.28 M, a 69.96% change year over year.
  • Eupraxia Pharmaceuticals Inc. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2022 was USD 4.28 M, a -39.03% change year over year.
  • Eupraxia Pharmaceuticals Inc. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2021 was USD 7.03 M, a 605.18% change year over year.
  • Eupraxia Pharmaceuticals Inc. Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2020 was USD 996.38 K, a -57.04% change year over year.
Key Data
Date Selling, General, and Administrative Expenses (SG&A) Research and Development (R&D) Expenses Revenue Revenue